Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is 54.97 as of 2026-10-06T18:06:46.185Z.
Consensus retrieved: 2026-10-06T10:00:53.530Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T18:06:46.185Z.
Quote observation: 2026-10-06T18:05:22.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 910caa8056250a98c6dba3c9bb66883dbb084468cd81c957cd22bc1e41af4ee2
Forward PE Ratio (54.97) = Dated Quote Price ($65.84) / Consensus Forward EPS ($1.20)
FORWARD PE RATIO
54.97
SECTOR MEDIAN · HEALTHCARE
19.84
median of 189 covered companies
CURRENT VS SECTOR MEDIAN
+177.07%
vs the sector median at left
CareDx, Inc
Market Cap
$3.41B
Forward PE Ratio
54.97
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| CareDx, Inc (CDNA) | $3.41B | 54.97 |
| Pulse Biosciences, Inc. (PLSE)vs › | $3.41B | N/A |
| Acadia Pharmaceuticals Inc. (ACAD)vs › | $3.39B | 32.16 |
| Celcuity Inc. (CELC)vs › | $3.48B | N/A |
| IDEAYA Biosciences, Inc. (IDYA)vs › | $3.48B | N/A |
| Viking Therapeutics, Inc. (VKTX)vs › | $3.35B | N/A |
| Xenon Pharmaceuticals Inc. (XENE)vs › | $3.49B | N/A |
| Tango Therapeutics, Inc. (TNGX)vs › | $3.49B | N/A |
| Parabilis Medicines, Inc. (PBLS)vs › | $3.33B | N/A |
| iRhythm Technologies, Inc. (IRTC)vs › | $3.54B | N/A |
Trailing P/E
31.8
reported TTM EPS
Forward P/E
55.0
consensus EPS · fiscal year ending 2026-12-31
The gap between the two multiples is the consensus growth expectation: analysts' forward EPS of $1.20 implies -42.0% EPS decline vs the reported trailing $2.07.
At the dated quote price of $65.84, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $1.20 | $1.18 – $1.22 | 4 | 55.0x |
| 2027-12-31 | $1.29 | $1.27 – $1.31 | 4 | 51.0x |
| 2028-12-31 | $1.84 | $1.28 – $2.72 | 3 | 35.8x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
